The network as the target

Julie E. Baggs, Michael E. Hughes, John B. Hogenesch

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The conventional target centric model of drug discovery is pinned under the weight of prior success and the traditional problems of safety and efficacy for new molecules. An alternative to target centric drug development is to shift focus to the pathways that mediate both biology and pathophysiology. This method has the advantage of not requiring a priori knowledge of the small molecule target, but also comes with it several challenges including target determination. We suggest extending this notion more broadly across the drug discovery process using quantitative network structure-activity relationships (QNSAR), and discuss the steps necessary to test the hypothesis that systems biology approaches can be used to improve the drug discovery process.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalWiley Interdisciplinary Reviews: Systems Biology and Medicine
Issue number2
StatePublished - Mar 2010


Dive into the research topics of 'The network as the target'. Together they form a unique fingerprint.

Cite this